Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Insert - p. iii 7. Aims and scope of series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. iii 8. About the Series Editor - p. ix 9. Aims and Scope of Volume - p. x 10. About the Volume Editors - p. xiii 11. Preface - p. xv 12. Contributors - p. xxi 13. Chapter 1. Mechanisms of immune suppression in glioblastoma - p. 1 14. Chapter 2. Applied cancer immunogenomics in glioblastoma - p. 19 15. Chapter 3. Heat shock protein vaccines in glioblastoma - p. 39 16. Chapter 4. Virotherapy treatment of central nervous system tumors - p. 58 17. Chapter 5. Adoptive cell therapy for glioma - p. 73 18. Chapter 6. Immune checkpoint blockade therapy in high-grade glioma - p. 91 19. Chapter 7. Immunomodulatory roles of myeloid cells in gliomas - p. 109 20. Chapter 8. Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy - p. 127 21. Chapter 9. Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma - p. 153 22. Index - p. 163
Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Insert - p. iii 7. Aims and scope of series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. iii 8. About the Series Editor - p. ix 9. Aims and Scope of Volume - p. x 10. About the Volume Editors - p. xiii 11. Preface - p. xv 12. Contributors - p. xxi 13. Chapter 1. Mechanisms of immune suppression in glioblastoma - p. 1 14. Chapter 2. Applied cancer immunogenomics in glioblastoma - p. 19 15. Chapter 3. Heat shock protein vaccines in glioblastoma - p. 39 16. Chapter 4. Virotherapy treatment of central nervous system tumors - p. 58 17. Chapter 5. Adoptive cell therapy for glioma - p. 73 18. Chapter 6. Immune checkpoint blockade therapy in high-grade glioma - p. 91 19. Chapter 7. Immunomodulatory roles of myeloid cells in gliomas - p. 109 20. Chapter 8. Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy - p. 127 21. Chapter 9. Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma - p. 153 22. Index - p. 163
